Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years

Table 3 Comparison of 2-year radiographic progression among tumor necrosis factor antagonists

		Baseline characteristics		Radiographic progression results
Cohort	Number^a	Disease duration, years^b	mSASSS value^b	Mean mSASSS change from baseline to year 2^b	Between-cohort Pvalue
Etanercept [2]	257	10 ± 8.5	16 ± 18.3	0.9 ± 2.5	0.996
OASIS	175	11 ± 8.5	14 ± 17.6	1.0 ± 3.2
Infliximab [3]	156	10.2 ± 8.7	17.7 ± 17.9	0.9 ± 2.6	0.541
OASIS	165	11.3 ± 8.6	15.8 ± 18.1	1.0 ± 3.2
Adalimumab	307	11.2 ± 9.3	19.8 ± 19.3	0.8 ± 2.6	0.771
OASIS	169	11.3 ± 8.6	15.8 ± 17.6	0.9 ± 3.3

^aNumber of patients with a baseline and a year-2 radiograph. ^bValues are mean ± standard deviation. mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; OASIS, Outcome in Ankylosing Spondylitis International Study.

ISSN: 1478-6362